Generic Medications in Psychiatry (June)

Date of Issue: 06/01/2009 | Volume: 7 | Number: 6

Issue Links:Learning Objectives | Editorial Information

Teaser to be posted soon.

In This Issue


L-Methylfolate for Depression: The Real Deal?

You may have already seen journal advertisements for Deplin (, a formulation of L-methylfolate produced by a company called Pamlab LLC. Touted as an “antidepressant food,” Pamlab claims it is “a first choice in depression augmentation.”

Read More
Research Update

Seroquel XR For Depression? Two Recent Studies Weigh In

Topics: Antidepressants

Suddenly, psychopharmacology has apparently become “all Seroquel, all the time.” AstraZeneca’s atypical antipsychotic (generic name, extended release quetiapine), which already had FDA approval for schizophrenia and bipolar mania, recently won approval for bipolar depression, and is now pushing for indications in depression and generalized anxiety disorder (GAD).

Read More
Expert QA

Brand-Names vs. Generics: Results from a Meta-Analysis

Dr. Kesselheim, you and your colleagues just published an intriguing paper on generic medications (Kesselheim AS et al., JAMA 2008;300(21):2514-2526). I’d like to start by asking you to explain the generic approval process. What does the FDA do to give its seal of approval to generic medications?

Read More